Disease States

Table of Contents

Breast Cancer

NCT0292862 A Phase 1/2a Multicenter, Open-Label Study of LYC-55716 in Adult Subjects with Locally Advanced or Metastatic Cancer

Tial Information:
https://clinicaltrials.gov/ct2/show/NCT02929862?term=LYCERA&rank=3

CCI Research Team Contact:

Avitra Bone, RN BSN OCN
256-705-4283
avitrab@ccihsv.com

NCT02580448 A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients With Advanced Breast Cancer

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT02580448?term=VT-464&rank=5

CCI Research Team Contact:

Leslie Smoot, RN
256-705-4246
leslies@ccihsv.com

NCT02659514: Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT02659514?term=NCT02659514&rank=1

CCI Research Team Contact:

Lesllie Smoot, RN
256-705-4246
leslies@ccihsv.com

Colorectal Cancer

NCT0292862 A Phase 1/2a Multicenter, Open-Label Study of LYC-55716 in Adult Subjects with Locally Advanced or Metastatic Cancer

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT02929862?term=LYCERA&rank=3

CCI Research Team Contact:

Avitra Bone, RN BSN OCN
256-705-4283
avitrab@ccihsv.com

NCT02599324: A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT02599324?term=NCT02599324&rank=1

CCI Research Team Contact:

Avitra Bone, RN BSN OCN
256-705-4283
avitrab@ccihsv.com

Gastric Cancer

NCT0292862 A Phase 1/2a Multicenter, Open-Label Study of LYC-55716 in Adult Subjects with Locally Advanced or Metastatic Cancer

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT02929862?term=LYCERA&rank=3

CCI Research Team Contact:

Avitra Bone, RN BSN OCN
256-705-4283
avitrab@ccihsv.com

NCT02599324: A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT02599324?term=NCT02599324&rank=1

CCI Research Team Contact:

Avitra Bone, RN BSN OCN
256-705-4283
avitrab@ccihsv.com

Genitourinary Cancer

NCT0292862 A Phase 1/2a Multicenter, Open-Label Study of LYC-55716 in Adult Subjects with Locally Advanced or Metastatic Cancer

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT02929862?term=LYCERA&rank=3

CCI Research Team Contact:

Avitra Bone, RN BSN OCN
256-705-4283
avitrab@ccihsv.com

NCT02599324: A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT02599324?term=NCT02599324&rank=1

CCI Research Team Contact:

Avitra Bone, RN BSN OCN
256-705-4283
avitrab@ccihsv.com

Leukemia

NCT01994382: A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphoncytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B Cell or T Cell Non-Hodgkin Lymphoma (NHL)

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT01994382?term=Portola&recr=Open&rank=1

CCI Research Team Contact:

Avitra Bone, RN, BSN, OCN
256-705-4283
avitrab@ccihsv.com

NCT02594384: Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimeyslate Capsules) Administered Orally in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT02594384?term=LAM&recr=Open&rank=1

NCT02742090 A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients With Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK (Bruton Tyrosine Kinase) or PI3K-Delta (Phosphoinositide-3-kinase) Inhibitor Therapy

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT02742090?term=TGR1202&rank=10

CCI Research Team Contact:

Kathy Cutter, RN BSN
256-705-4248
kathyc@ccihsv.com

NCT02612311: A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination With TGR-1202 Compared to Obinutuzumab in Combination With Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT02612311?term=TG+Therapeutics&recr=Open&rank=5

CCI Research Team Contact:

Kathy Cutter, RN BSN
256-705-4248
kathyc@ccihsv.com

Lung Cancer

NCT0292862 A Phase 1/2a Multicenter, Open-Label Study of LYC-55716 in Adult Subjects with Locally Advanced or Metastatic Cancer

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT02929862?term=LYCERA&rank=3

CCI Research Team Contact:

Avitra Bone, RN BSN OCN
256-705-4283
avitrab@ccihsv.com

NCT02544633: Phase 2, Parallel-Arm Study of MGCD265 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT02544633?term=Mirati&rank=1

CCI Research Team Contact:

Leslie Smoot, RN
256-705-4246
leslies@ccihsv.com

NCT02027428: Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT02027428?term=NCT02027428&rank=1

CCI Research Team Contact:

Leslie Smoot, RN
256-705-4246
leslies@ccihsv.com

Lymphoma

NCT01994382: A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphoncytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B Cell or T Cell Non-Hodgkin Lymphoma (NHL)

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT01994382?term=Portola&recr=Open&rank=1

CCI Research Team Contact:

Avitra Bone, RN, BSN, OCN
256-705-4283
avitrab@ccihsv.com

NCT02594384: Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimeyslate Capsules) Administered Orally in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT02594384?term=LAM&recr=Open&rank=1

NCT02006485: A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Combination With TGR-1202, a Novel PI3k Delta Inhibitor, in Patients With B-cell Malignancies

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT02006485?term=NCT02006485&rank=1

CCI Research Team Contact:

Kathy Cutter, RN BSN
256-705-4248
kathyc@ccihsv.com

NCT02874404: TGR-1202 and Ibrutinib in Treating Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT02874404?term=TGR+1202&rank=4

CCI Research Team Contact:

Kathy Cutter, RN BSN
256-705-4248
kathyc@ccihsv.com

Pancreatic Cancer

NCT0292862 A Phase 1/2a Multicenter, Open-Label Study of LYC-55716 in Adult Subjects with Locally Advanced or Metastatic Cancer

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT02929862?term=LYCERA&rank=3

CCI Research Team Contact:

Avitra Bone, RN BSN OCN
256-705-4283
avitrab@ccihsv.com

NCT02436668: A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 2/3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT02436668?term=PCYC1137&rank=1

CCI Research Team Contact:

Avitra Bone, RN BSN OCN
256-705-4283
avitrab@ccihsv.com

Supportive Care and Disease Registries

CHS BioBank (ABRT) Trial
Trial Information:
http://www.conversantbio.com/oncology

CCI Research Team Contact:

Megan Hargrove
256-327-4227
meganh@ccihsv.com